RSS   Newsletter   Contact   Advertise with us
Post Online Media
Post Online Media Magazine

Glenmark Pharmaceuticals to partner with Novartis in Brazil

Share on Twitter Share on LinkedIn
Christian Fernsby |
Novartis
LatAm   Glenmark Farmacêutica Ltda has entered into an exclusive partnership agreement

Glenmark Pharmaceuticals announced that its Brazilian subsidiary, Glenmark Farmacêutica Ltda has entered into an exclusive partnership agreement with Novartis Biosciences, a subsidiary of Novartis, for three respiratory products indicated towards treatment of the symptoms of chronic obstructive pulmonary disease (COPD) in Brazil.

This agreement will be effective from July 01, 2019 onwards.

The products involved in the agreement are Seebri (Glycopyrronium bromide), Onbrize (Indacaterol) and Ultibro (combination of Indacaterol and Glycopyrronium), which are indicated for relief of symptoms in adults with COPD.

Under the terms of the agreement, Novartis remains the holder of the registration of these medicines and will be responsible to manufacture them with all technical excellence in line with its global commitment to quality, effectiveness and safety.

Glenmark will be responsible for promoting, commercializing and distributing of these products in Brazil.


What to read next
POST Online Media Contact